Is there any clinical reason to take rosuvastatin and simvastatin concurrently?

No Valid Clinical Reason to Take Rosuvastatin and Simvastatin Concurrently

There is no clinical indication to prescribe rosuvastatin and simvastatin simultaneously, and doing so would be inappropriate and potentially harmful. Both medications are HMG-CoA reductase inhibitors (statins) that work through the same mechanism—inhibiting cholesterol synthesis in the liver 1. Using two statins together provides no additional therapeutic benefit while substantially increasing the risk of serious adverse effects, particularly myopathy and rhabdomyolysis 1, 2, 3.

Why Dual Statin Therapy Makes No Sense

Mechanism of Action

• All statins competitively inhibit the same enzyme (HMG-CoA reductase) at the same site 1
• Adding a second statin does not enhance LDL-cholesterol lowering beyond what a single, appropriately dosed statin achieves 4
• The drugs would essentially compete with each other for the same binding site, making combination therapy pharmacologically illogical 1

Safety Concerns

• Both rosuvastatin and simvastatin independently carry risks of myopathy and rhabdomyolysis 2, 3
• Combining two statins would theoretically double the exposure to statin-related adverse effects without doubling efficacy 1
• The FDA labeling for both medications discusses drug interactions that increase myopathy risk, but never suggests combining with another statin 2, 3

What Should Be Done Instead

If Current Statin is Inadequate

Switch to a more potent statin or increase the dose of the current statin rather than adding a second one 5, 4:

• Rosuvastatin is generally more potent than simvastatin at equivalent doses 5, 4
• Rosuvastatin 40 mg achieves approximately 58.7% LDL-C reduction, while simvastatin 10 mg achieves only 32.5% reduction 4
• Patients switched from simvastatin to rosuvastatin achieve significantly greater LDL-C reduction (18.4% additional reduction) 5

If Maximum Statin Dose is Insufficient

Add a non-statin lipid-lowering agent 1:

• Ezetimibe is the preferred add-on therapy, providing an additional 15-20% LDL-C reduction 4

• Combined statin-ezetimibe therapy shows less variability in LDL-C response compared to statin monotherapy 4

• Rosuvastatin 40 mg combined with ezetimibe achieves up to 71.6% LDL-C reduction 4

• PCSK9 inhibitors for patients requiring further LDL-C lowering beyond statin-ezetimibe combination 6

• Fenofibrate may be considered if triglycerides are elevated, though gemfibrozil should be avoided with statins due to increased myopathy risk 1

Common Pitfall to Avoid

The most likely scenario where dual statin therapy might occur is through prescribing error or lack of medication reconciliation 7:

• Always review the patient's complete medication list before prescribing any statin 7
• If a patient presents on two statins, this represents a medication error that should be corrected immediately 7
• Discontinue one statin and optimize the dose of the remaining agent based on LDL-C goals 5, 4